J.P. Marvel Investment Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.46M | Hold |
37,286
| – | – | 0.97% | 23 |
|
|
2026
Q1 | $6.43M | Buy |
37,286
+52
| +0.1% | +$9.64K | 0.91% | 27 |
|
|
2025
Q4 | $7.43M | Hold |
37,234
| – | – | 1.03% | 22 |
|
|
2025
Q3 | $5.83M | Buy |
37,234
+170
| +0.5% | +$27K | 0.85% | 28 |
|
|
2025
Q2 | $5.62M | Sell |
37,064
-370
| -1% | -$49.3K | 0.91% | 28 |
|
|
2025
Q1 | $5.63M | Sell |
37,434
-170
| -0.5% | -$28.5K | 0.97% | 31 |
|
|
2024
Q4 | $6.94M | Sell |
37,604
-1,827
| -5% | -$352K | 1.15% | 24 |
|
|
2024
Q3 | $7.77M | Sell |
39,431
-45
| -0.1% | -$9.35K | 1.27% | 24 |
|
|
2024
Q2 | $8.15M | Sell |
39,476
-10
| -0% | -$2.27K | 1.34% | 21 |
|
|
2024
Q1 | $10.7M | Buy |
39,486
+709
| +2% | +$169K | 1.85% | 15 |
|
|
2023
Q4 | $9.17M | Sell |
38,777
-25
| -0.1% | -$4.92K | 1.82% | 17 |
|
|
2023
Q3 | $7.6M | Hold |
38,802
| – | – | 1.64% | 21 |
|
|
2023
Q2 | $8.16M | Buy |
38,802
+2,380
| +7% | +$474K | 1.7% | 19 |
|
|
2023
Q1 | $7.35M | Buy |
36,422
+100
| +0.3% | +$22.7K | 1.66% | 22 |
|
|
2022
Q4 | $7.91M | Hold |
36,322
| – | – | 1.86% | 23 |
|
|
2022
Q3 | $7.15M | Sell |
36,322
-3
| -0% | -$648 | 1.82% | 22 |
|
|
2022
Q2 | $7.77M | Hold |
36,325
| – | – | 1.87% | 22 |
|
|
2022
Q1 | $10.3M | Buy |
36,325
+507
| +1% | +$156K | 2.1% | 20 |
|
|
2021
Q4 | $13.5M | Buy |
35,818
+440
| +1% | +$171K | 2.64% | 11 |
|
|
2021
Q3 | $14.6M | Buy |
35,378
+80
| +0.2% | +$33.2K | 4.4% | 6 |
|
|
2021
Q2 | $13.1M | Buy |
35,298
+751
| +2% | +$251K | 2.78% | 11 |
|
|
2021
Q1 | $10M | Buy |
34,547
+1,233
| +4% | +$343K | 2.37% | 17 |
|
|
2020
Q4 | $8.32M | Buy |
33,314
+104
| +0.3% | +$24.8K | 2.15% | 17 |
|
|
2020
Q3 | $7.52M | Buy |
33,210
+80
| +0.2% | +$16.6K | 2.16% | 16 |
|
|
2020
Q2 | $5.78M | Buy |
33,130
+120
| +0.4% | +$19.2K | 1.83% | 24 |
|
|
2020
Q1 | $4.17M | Buy |
33,010
+1,390
| +4% | +$208K | 1.58% | 27 |
|
|
2019
Q4 | $4.83M | Hold |
31,620
| – | – | 1.4% | 35 |
|
|
2019
Q3 | $4.19M | Buy |
+31,620
| New | +$4.24M | 1.34% | 33 |
|
|
2019
Q1 | $4.22M | Buy |
29,060
+7,500
| +35% | +$985K | 1.37% | 33 |
|
|
2018
Q4 | $2.44M | Buy |
+21,560
| New | +$2.7M | 0.88% | 40 |
|
|
2018
Q2 | $1.76M | Hold |
15,710
| – | – | 0.54% | 52 |
|
|
2018
Q1 | $1.68M | Hold |
15,710
| – | – | 0.52% | 54 |
|
|
2017
Q4 | $1.72M | Hold |
15,710
| – | – | 0.52% | 54 |
|
|
2017
Q3 | $1.7M | Sell |
15,710
-60
| -0.4% | -$6.16K | 0.54% | 53 |
|
|
2017
Q2 | $1.59M | Sell |
15,770
-20
| -0.1% | -$1.84K | 0.53% | 51 |
|
|
2017
Q1 | $1.42M | Sell |
15,790
-1,860
| -11% | -$158K | 0.47% | 52 |
|
|
2016
Q4 | $1.34M | Buy |
17,650
+3,000
| +20% | +$228K | 0.46% | 51 |
|
|
2016
Q3 | $1.22M | Buy |
14,650
+520
| +4% | +$43.6K | 0.43% | 51 |
|
|
2016
Q2 | $1.17M | Buy |
+14,130
| New | +$1.16M | 0.41% | 52 |
|
Other funds holding CRL
AI
J.P. Marvel Investment Advisors's CRL Position: Q2 2026 in Review
J.P. Marvel Investment Advisors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 37,286 shares worth $8.46M. The position accounts for 0.97% of the portfolio, ranked #23.
J.P. Marvel Investment Advisors first reported a position in CRL in Q2 2016 and has held it in 39 quarters since. The position peaked at $14.6M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- J.P. Marvel Investment Advisors held 37,286 shares of Charles River Laboratories worth $8.46M as of Q2 2026.
- J.P. Marvel Investment Advisors left its Charles River Laboratories share count unchanged in Q2 2026.
- Charles River Laboratories made up 0.97% of J.P. Marvel Investment Advisors's portfolio in Q2 2026, its #23 holding.
- J.P. Marvel Investment Advisors first reported a position in Charles River Laboratories in Q2 2016 and has held it in 39 quarters since.
- J.P. Marvel Investment Advisors's Charles River Laboratories position peaked at $14.6M in Q3 2021.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on J.P. Marvel Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.